STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’

STAT PlusExclusive Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’ Telehealth company gets ASCO certification for navigating patient care, supporting in-person clinical team Manage alerts for this article Email this article Share this article By Angus ChenMay 6, 2026 Cancer Reporter Angus Chen[email protected]Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more. You can reach Angus on Signal at angus.08. The way Color Health’s CEO Othman Laraki sees it, cancer has a scaling problem. New science regularly sets new standards of care, increasing the intricacy of managing an already complex illness. Cancer patients are multiplying faster than oncologists, Laraki said, and costs, too, are exploding. All this makes it difficult for everyone to receive the best possible therapy. The solution that the Silicon Valley executive sees is inevitable. “In our mind, the only way this is going to be addressed and solved is in a virtual first, AI-driven manner,” Laraki said. “In the coming years, the biggest cancer centers will be virtual first.”Advertisement Virtual care for cancer may sound like an oxymoron. After all, the pillars of cancer treatment are almost all hands-on: surgery, radiation, infusions, and the like. But Color Health has been building out a virtual cancer clinic — including a virtual “tumor board” of multidisciplinary experts — that the company says can deliver and manage care at a high quality. The company just received a certification from the American Society of Clinical Oncology to back it up. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Cancer, health tech, Physicians, STAT+, Telehealth Submit a correction requestReprints Angus Chen Cancer Reporter Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more. You can reach Angus on Signal at angus.08. Newsletter Critical updates on the fast-moving world of cancer research, treatment, and patient care Recommended The Readout May 6, 2026 STAT Plus: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price D.C. Diagnosis May 5, 2026 STAT Plus: A new attack on AMA’s billing codes Advertisement The Readout May 5, 2026 STAT Plus: Are analysts too quick to gloss over Lilly’s liver case? Health Care Inc. Newsletter May 4, 2026 STAT Plus: Pump the brakes on AI, buddy; and deposition deadlock The Readout May 4, 2026 UCB to acquire maker of antibody treatments for autoimmune diseases Subscriber Picks